Теанин
Bryan, J. 2008. Psychological effects of dietary components of tea: caffeine and Ltheanine. Nutrition Review 66(2): 82–90.
Dimpfel, W., A. Kler, E. Kriesl, et al. 2007. Source density analysis of the human EEG after ingestion of a drink containing decaffeinated extract of green tea enriched with L- theanine and theogallin. Nutritional Neuroscience 10(3–4): 169–180.
Nobre, A. C., A. Rao, and G. N. Owen. 2008. L- theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition 17(Suppl. 1): 167–168.
Rogers, P. J., J. E. Smith, S. V: Heatherley, et al. 2008. Time for tea: Mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology 195(4): 569–577.
Цинк
Arnold, L. Е., Н. Bozzolo, J. Hollway, et al. 2005. Serum zinc correlates with parent- and teacher- rated inattention in children with attention- deficit/hyperactivity disorder. Journal of Child & Adolescent Psychopharmacology 15(4): 628–636.
Bilici, M., F. Yildirim, S. Kandil, et al. 2004. Double- blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Progress in Neuropsychopharmacology & Biological Psychiatry 28(1): 181–190.
Yorbik, O., M. F. Ozdag, A. Olgun, et al. 2008. Potential effects of zinc on information processing in boys with attention deficit hyperactivity disorder. Progress in Neuropsychopharmacology & Biological Psychiatry 32(3): 662–667.
Глава 7
Amen, D. G., and L. C. Routh. 2003. Healing Anxiety and Depression. New York: Putnam.
Антидепрессивный эффект физических упражнений
Babyak, M., J. A. Blumenthal, S. Herman, et al. 2000. Exercise treatment for major depression: Maintenance of therapeutic benefit at 10 months. Psychosomatic Medicine 62(5): 633–638.
Blumenthal, J. A., M. A. Babyak, P. M. Doraiswamy, et al. 2007. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosomatic Medicine 69(7): 587–596.
Kessler, R. С., P. A. Berglund, O. Dernier, et al. 2005. Lifetime prevalence and ageof-onset distributions of DSM- IV disorders in the National Comorbidity Survey Replication (NCS- R). Archives of General Psychiatry 62(6): 593–602.
ГАМК
Abdou, А. М., S. Higashiguchi, К. Horie, et al. 2006. Relaxation and immunity enhancement effects of gamma- aminobutyric acid (GABA) administration in humans. Biofactors 26(3): 201–208.
Cocito, L., A. Bianchetti, L. Bossi, et al. 1994. GABA 30 and phosphati-dylserine in human photosensitivity: A pilot study. Epilepsy Research 17: 49–53.
Green, M. L., R. G. Green, and W. Santoro. 1988. Daily relaxation modifies serum and salivary immunoglobulins and psychophysi-ologic symptom severity. Biofeedback &. Self Regulation 13: 187–199.
Loeb, С., E. Benassi, G. P. Bo, et al. 1987. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Epilepsy Research 1: 209–212.
Гипербарическая оксигенация
Hopkins, R. О., L. К. Weaver, К. J. Valentine, et al. 2007. Apolipoprotein E genotype and response of carbon monoxide poisoning to hyperbaric oxygen treatment. American Journal of Respiratory and Critical Care Medicine 176(10): 1001–1006.
Lo, C. P., S. Y. Chen, M. C. Chou. 2007. Diffusion- tensor MR imaging for evaluation of the efficacy of hyperbaric oxygen therapy in patients with delayed neuropsychiatric syndrome caused by carbon monoxide inhalation. European Journal of Neurology 14(7): 777–782.
Инозитол
Barak, Y., J. Levine, A. Glasman, et al. 1996. Inositol treatment of Alzheimer’s disease: a double-blind, cross- over placebo controlled trial. Progress in europsychopharmacology and Biological Psychiatry 20(4): 729–735.
Carey, Р. D., J. Warwick, В. Н. Harvey, et al. 2004. Single photon emission computed tomography (SPECT) in obsessive- compulsive disorder before and after treatment with inositol. Metabolic Brain Disease 19(1–2): 125–134.
Chengappa, K. N., J. Levine, S. Gershon, et al. 2000. Inositol as an addon treatment for bipolar depression. Bipolar Disorders 2(1): 47–55.
Fux, M., J. Levine, A. Aviv, et al. 1996. Inositol treatment of obsessive-compulsive disorder. American Journal of Psychiatry 153(9): 1219–1221.
Кава-кава
Attele, A. S., J. T. Xie, C. S. Yuan. 2000. Treatment of insomnia: an alternative approach. Alternative Medicine Review 5(3): 249–259.
Basch, E., C. Ulbricht, P. Hammerness, et al. 2002. Kava monograph. Journal of Herbal Pharmacotherapy 2(4): 65–91.
Boerner, R. J., and S. Klement. 2004. Attenuation of neuroleptic- induced extrapyramidal side effects by Kava special extract WS 1490. Wiener Medizin i — sche Wochenschrift 154(21–22): 508–510.
Pittler, M. H., and E. Ernst. 2003. Kava extract for treating anxiety. Cochrane Database of Systatic Reviews Issue 1. Art. No.: CD003383. DOI: 10. 1002/14651858. CD003383.
Scherer, J. 1998. Kava-kava extract in anxiety disorders: an outpatient observational study. Advances in Therapy 15(4): 261–269.
Кетогенная диета для эпилепсии и других психиатрических расстройств.
Farasat, S., Е. Н. Kossoff, D. J. Pillas, et al. 2006. The importance of parental expectations of cognitive improvement for their children with epilepsy prior to starting the ketogenic diet. Epilepsy & Behavior 2006 8(2): 406–410.
Kossoff, Е. Н., L. С. Laux, R. Blackford, et al. 2008. When do seizures usually improve with the ketogenic diet? Epilepsia 49(2): 329–333.
Martinez, C. G, P. L. Pyzik, and E. H. Kossoff. 2007. Discontinuing the ketogenic diet in seizure- free children: recurrence and risk factors. Epilepsia 48(1): 187–190.
Neal, E. G., H. Chaffe, R. H. Schwartz, et al. 2008. The ketogenic diet for the treatment of childhood epilepsy: A randomised controlled trial. Lancet Neurology 7(6): 500–506.
Аутизм
Evangeliou, A., I. Vlachonikolis, H. Mihailidou, et al. 2003. Application of a ketogenic diet in children with autistic behavior: pilot study. Journal of Child Neurology 18(2): 113–118.
Поведение
Murphy, P, S. S. Likhodii, M. Hatamian, et al. 2005. Effect of the ketogenic diet on the activity level of Wistar rats. Pediatric Research 57(3): 353–357.
Pulsifer, M. B., J. M. Gordon, J. Brandt, et al. Effects of ketogenic diet on development and behavior: preliminary report of a prospective study. Developmental Medicine & Child Neurology 43(5): 301–306.
Биполярное расстройство
El — Mallakh, R. S., and M. E. Paskitti. 2001. The ketogenic diet may have moodstabilizing properties. Medical Hypotheses 57(6): 724–726.
Yaroslavsky, Y., Z. Stahl, and R. H. Belmaker. 2002. Ketogenic diet in bipolar illness. Bipolar Disorders 4(1): 75.
Жирные кислоты омега-3/рыбий жир и депрессия
Conklin, S. М., S. В. Manuck, J. К. Yao, et al. High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosomatic Medicine 69(9): 932–934.
Grenyer, В. Е, Т Crowe, В. Meyer, et al. 2007. Fish oil supplementation in the treatment of major depression: a randomised double- blind placebocontrolled trial. Progress in Neuropsychopharmacology and Biological Psychiatry 31(7): 1393–1396.
Stoll, A. L., C. A. Locke, L. B. Marangell, et al. 1999. Omega-3 fatty acids and bipolar disorder: A review. Prostaglandins, Leukotrienes & Essential Fatty Acids 60(5–6): 329–337.
Валериана
Balderer, G., and A. A. Borbely. 1985. Effect of valerian on human sleep. Psychopharmacology 87(4): 406–409.
Coxeter, P. D., P. J. Schluter, H. L. Eastwood, et al. 2003. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n- of- 1 trials. Complementary Therapies in Medicine 11(4): 215–222.
Diaper, A., and I. Hindmarch. 2004. A double- blind, placebo- controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep- disturbed older adults. Phytotherapy Research 18(10): 831–836.
Kuhlmann, J., W. Berger, H. Podzuweit, et al. 1999. The influence of valerian treatment on «reaction time, alertness and concentration» in volunteers. Pharmacopsychiatry 32(6): 235–241.
Витамин D и депрессия
Armstrong, D. J., G. K. Meenagh, I. Bickle, et al. 2007. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clinical Rheumatology 26(4): 551–554.
Berk, M., К. M. Sanders, J. A. Pasco, et al. 2007. Vitamin D deficiency may play a role in depression. Medical Hypotheses 69(6): 1316–1319.
Wilkins, С. Н., Y. I. Sheline, С. М. Roe, et al. 2006. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. American Journal of Geriatric Psychiatry 14(12): 1032–1040.
Глава 8
Гинкго билоба
Burns, N., J. Bryan, and T. Nettelbeck. 2006. Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults. Human Psychopharmacology 21(1): 27–37.
Dodge, H., T. Zitzelberger, B. Oken, et al. 2008. A randomized placebo-controlled trial of ginkgo biloba for the prevention of cognitive decline. Neurology 70(19): 1809–1817.
Hartley, D., L. Heinze, S. Elsabagh, et al. 2003. Effects on cognition and mood in postmenopausal women of 1- week treatment with Ginkgo biloba. Pharmacology Biochemistry and Behavior 75(3): 711–720.
Le Bars, P. L. 2003. Response patterns of EGb 761 in Alzheimer’s disease: influence of neuropsychological profiles. Pharmacopsychiatry 36(Suppl. 1): S50-55.
Le Bars, P. L., and J. Kastelan. 2000. Efficacy and safety of a Ginkgo biloba extract. Public Health Nutrition 3(4A): 495–499.
Mix, J., and W. Crews. 2002. A double- blind, placebo- controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: Neuropsychological findings. Human Psychopharmacology 17(6): 267–277.
Nathan, P, S. Tanner, J. Lloyd, et al. 2004. Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans. Human Psychopharmacology 19(2): 91–96.
Singh, В., Н. Song, X. Liu, et al. 2004. Dangshen (Codonopsis pilosula) and Bai guo (Ginkgo biloba) enhance learning and memory. Alternative Therapies in Health & Medicine 10(4): 52–56.
Гюперзин A
Aisen, P. 2007. A multi- center, double- blind, placebo- controlled therapeutic trial to determine whether natural huperzine A improves cognitive function. Clinical Trials.
Ved, H., M. Koenig, J. Dave, et al. 1997. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. NeuroReport 8(4): 963–967.
Xu, S., Z. Cai, Z. Qu, et al. 1999. Huperzine- A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 20(6): 486–490.
Zhang, R., X. Tang Y. Han, et al. 1991. Drug evaluation of huperzine A in the treatment of senile memory disorders. Zhongguo Yao Li Xue Bao 12(3): 250–252.
Мелатонин
Almeida Montes, L. G., M. P. Ontiveros Uribe, S. J. Cortes, et al. 2003. Treatment of primary insomnia with melatonin: A double- blind, placebo- controlled, crossover study. Journal of Psychiatry & Neuroscience 28(3): 191–196.
Cardinali, D. P, E. Gvozdenovich, and M. R. Kaplan. 2002. A doubleblind placebo-controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinology Letters 23(1): 55–60.
Dowling, G. A., R. L. Burr, E. J. Van Someren, et al. 2008. Melatonin and brightlight treatment for rest- activity disruption in institutionalized patients with Alzheimer’s disease. Journal of the American Geriatrics Society 56(2): 239–246.
Pillar, G., Е. Shahar, N. Peled, et al. 2000. Melatonin improves sleep-wake patterns in psychomotor retarded children. Pediatric Neurology 23(3): 225–228.
Smits, M. G., E. E. Nagtegaal, H. J. van der, et al. 2001. Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial. Journal of Child Neurology 16(2): 86–92.
Фосфатидилсерин
Crook, T., W. Petrie, C. Wells, et al. 1992. Effects of phosphatidyl-serine in Alzheimer’s disease. Psychopharmacology Bulletin 28: 61–66.
